Quantitative analysis of iobitridol in an injectable preparation by 1H NMR spectroscopy

Quantitative analysis of iobitridol in an injectable preparation by 1H NMR spectroscopy

Accepted Manuscript Title: analysis of Iobitridol in an injectable preparation by 1 H NMR spectroscopy Author: Anna Borioni Gianluca Gostoli Elena Bos...

559KB Sizes 0 Downloads 51 Views

Accepted Manuscript Title: analysis of Iobitridol in an injectable preparation by 1 H NMR spectroscopy Author: Anna Borioni Gianluca Gostoli Elena Boss`u Isabella Sestili PII: DOI: Reference:

S0731-7085(14)00047-8 http://dx.doi.org/doi:10.1016/j.jpba.2014.01.030 PBA 9435

To appear in:

Journal of Pharmaceutical and Biomedical Analysis

Received date: Revised date: Accepted date:

14-11-2013 14-1-2014 21-1-2014

Please cite this article as: A. Borioni, G. Gostoli, E. Boss`u, I. Sestili, analysis of Iobitridol in an injectable preparation by 1 H NMR spectroscopy., Journal of Pharmaceutical and Biomedical Analysis (2014), http://dx.doi.org/10.1016/j.jpba.2014.01.030 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

[rel]

*Graphical Abstract

General ------DATE = 2013/04/23 TIME = 13:25 INSTRUM = spect PULPROG = zgpr

HO O O

I HN

OH

N

F1 (1H) ------------SI = 65536 SF = 400.06 SW_p = 8012.821

OH I

I N

0.2

O

ip t

OH

0.0

0.1

OH

3.5

3.0

[ppm ]

Ac

ce pt

ed

M

an

us

4.0

cr

0.3

HO

Page 1 of 15

*Highlights (for review)

A qNMR method was used for direct assay determination of Iobitridol in an injectable formulation.



Experiments were carried out in deuterated alkaline water with 3,5 dinitrobenzoic acid as internal reference standard.



Method was validated assessing specificity, accuracy, precision, linearity, stability of samples and robustness.



Method proved suitable for routine controls especially when high sample throughput is required.

Ac

ce pt

ed

M

an

us

cr

ip t



Page 2 of 15

*Revised Manuscript

1

1

Quantitative analysis of Iobitridol in an injectable preparation by H NMR spectroscopy.

2

Anna Borioni*, Gianluca Gostoli, Elena Bossù, Isabella Sestili

3

Istituto Superiore di Sanità, Dipartimento del Farmaco, Rome Italy

4

*Corresponding author. Tel.: +39 06 49902516; fax: +39 06 49902625. E-mail address: [email protected].

5 1.

INTRODUCTION

ip t

6 7

Nuclear Magnetic Resonance spectroscopy in quantitative analysis (qNMR) experienced a remarkable

9

increase since about 2005-2007. In the field of pharmaceutics, qNMR raised the interest of the Official

10

Medicine Control Laboratories on the occasion of a criminal adulteration of heparine with a component

11

detectable by NMR spectroscopy and capillary electrophoresis [1,2].

12

As it is nowadays well documented, quantitative analytical methods based on NMR spectroscopy proved to be

13

highly robust, accurate and precise. In general, qNMR allows quantifying compounds, even in mixtures, at

14

sub-micromolar range and at the same time provides information on the chemical structure of the molecules

15

involved. [3,4,5,6,7]. Moreover, quantification by NMR spectroscopy is truly straightforward in comparison to

16

the chromatographic and spectroscopic techniques which require specific standards or correction factors. In

17

fact the area of the NMR signals is directly proportional to the quantity of the nuclei evoking the signal with no

18

dependence on how the nuclei are combined in chemical structures. This implies that molecules with no

19

chemical similarity to the analyte are used as internal reference standard [8].

20

In the present case we report the determination of the content of iobitridol in an injectable aqueous solution

21

(Fig. 1). Iobitridol is an iodine based contrast medium approved in Europe and in the USA for radiographic

22

diagnostic imaging in adult and children [9]. No EP or USP monograph for iobitridol is available though

23

similar substances such as iodixanol, iohexol, iopamidol, iopromide, iotrolan, iopanoic acid, iotalamic acid

24

and ioxaglic acid are reported in EP. For the large majority of them the assay is estimated by potentiometric

25

titration of iodine after a work up consisting of three operational steps (reduction by Zn, boiling, filtration

26

[10,11,12,13,14]

27

To the best of our knowledge only one determination of iobitridol in biological fluids by HPLC is reported [15].

28

We approached the NMR spectroscopy with the aim of accomplishing the quantification of the content of

29

iobitridol directly in the final formulation with minimal work up, in short time and by a medium field instrument

30

which is of prevalent and established use in qNMR. The NMR experiments were carried out according to the

Ac

ce pt

ed

M

an

us

cr

8

1 Page 3 of 15

31

general principles laid down in the general EP monograph 01/2009:20233 Nuclear Magnetic Resonance

32

Spectrometry.

33 34

2.

Materials and methods

36

2.1.

Chemicals and NMR Instrumentation

37

NMR experiments were recorded on a Bruker Avance instrument (Bruker Italia, Milano, Italy) operating at 400

38

MHz equipped with a 5 mm H/ C BBI probe and some preliminary spectra were acquired on a Bruker AM

39

operating at 700 MHz. The software Bruker Xwinnmr 3.1 was used for acquisition, the software Bruker

40

Topspin 1.2 was used for processing.

41

D2O (99.97%) and DMSO-d6 (99.80%) from Euriso Top (Saint-Aubin, France) were used as solvents. NMR 5

42

mm diameter tubes were purchased from CortecNet (Voisins-Le-Bretonneux, France).

43

Sodium hydroxide, 3-(Trimethylsilyl)-1-propanesulfonic acid, Maleic acid TraceCERT

44

Dinitrobenzoic acid TraceCERT CRM were purchased from Sigma- Aldrich (Sigma- Aldrich Italia, Milano,

45

Italy).

46

2.2.

47

Explorative spectra were performed on a solution of iobitridol injectable solution (260 mg) and maleic acid

48

(10 mg) in D2O (1 ml) and on a solution of iobitridol injectable solution (260 mg) and 3,5-dinitrobenzoic acid

49

(10 mg) in DMSO-d6 (1 ml).

50

For quantitative analysis an accurate weighted quantity of 3,5-dinitrobenzoic acid TraceCERT CRM (9.5

51

mg) and an accurate weighted quantity of the injectable solution here named iobitridol FP (260 mg), were

52

added to 1 ml of D2O previously made alkaline by addition of 1.4% w/w of solid sodium hydroxide. After five

53

minutes sonication, 0.7 ml of the solution was transferred into an NMR tube. The longest longitudinal

54

relaxation time (T1max) was experimentally determined with the Bruker inversion recovery pulse program

55

and resulted about 6 s owing to the 3,5-dinitrobenzoic acid protons. Spectra were acquired in triplicate for

56

each independent weighing unless otherwise specified. Acquisition parameters were: pulse length 45°,

57

delay 30 s, temperature 298 K, 16 scans and TD = 64K. The signal at 2.63 ppm (1H, multiplet) was

58

integrated for iobitridol and the singlet signal at 8.88 ppm (2H, doublet) of the 2,6 protons of 3,5-

59

dinitrobenzoic acid (DNB) was integrated as quantitative reference. In the processing an exponential function

us

cr

13

an

1

ip t

35

ce pt

ed

Sample preparation and NMR method

CRM, 3,5-

M

®

®

Ac

®

2 Page 4 of 15

60

of 0.3 Hz was applied, baseline was corrected by the software fifth order polynomial algorithm and phase

61

was adjusted manually. S/N always resulted above 350.

62

Assignation of the proton spectra was based on 2D H- H COSY [16], 2D H- H TOCSY [16], 2D H- H

63

ROESY [16] and 2D H- C HSCQ [17] diagrams. Standard Bruker pulse sequences were employed for 2D

64

experiments. Typically, data were collected for 2K TD and 512 increments (omonuclear 2D) and 2K TD and

65

256 increments for HSQC. Number of scans varied from 48 to 112, TOCSY mixing time was 100 ms, a delay

66

for a one bond H- C coupling constant of 140 Hz was set for HSQC and full proton decoupling of

67

achieved with the waltz16 sequence.

1

1

1

13

13

68 69

1

13

C was

cr

1

1

ip t

1

1

Results and discussion

71

3.1.

Choice of internal standard and dilution solvent

72

Explorative proton spectra were required to select the suitable solvent/reference standard system as the

73

proton spectrum of iobitridol is not easily predictable. Indeed, iobitridol could present partially restricted

74

rotation of the amide bonds around the aromatic ring giving rise to multiple rotational isomers possibly

75

displaying different NMR signals [18].

76

Solutions of iobitridol injectable solution together with maleic acid in D 2O or together with 3,5-dinitrobenzoic

77

acid (DNB) in DMSO-d6 were first used. Results were not conclusive because in both systems no

78

satisfactorily integrable protons of iobitridol could be identified. In D2O, the multiplet at 4.10 ppm attributable

79

to the single proton of the 2,3-dihydroxypropyl substituent (proton 2 Fig. 1) was the most promising candidate

80

for integration. However, it was not finally selected because of its proximity to the large water signal and

81

above all because its relative integral value did not account for a neat number of protons. This fact suggested

82

that the multiplet could represent a mixture of the signals of different conformational isomers.

83

As iobitridol showed a more resolved spectrum in D2O, the aqueous system was further exploited with the

84

purpose of improving signals resolution. In alkaline solution, the proton spectrum of iobitridol FP displayed a

85

distinct signal at about 2.6 ppm accounting for one proton integral which was assigned to the single proton of

86

the propylcarboxamino substituent of the benzene ring (proton 1 Fig.1). The chemical shift of proton 1

87

showed dependence on the sodium hydroxide concentration: the more alkaline the solution the more

88

shielded and resolved the proton was (Fig. 2). This trend may be attributable to the partial deprotonation of

89

the adjacent amide group in alkali: the consequent local increase of electron density led to an upfield shift of

us

3.

Ac

ce pt

ed

M

an

70

3 Page 5 of 15

the proton 1 signal [19]. A 1.4% w/w NaOH concentration in D2O represented a good compromise between a

91

satisfactory separation of the selected proton from the neighboring signals of the N-methyl groups and the

92

drawbacks of high alkalinity (potential active standard degradation and lengthening of the NMR pulse). 3,5-

93

Dinitrobenzoic acid was selected as quantitative reference standard because of its deshielded NMR signals

94

which assured no interferences with the iobitridol signals and with the strong water signal.

95

With the aim of reducing the set up of the acquisition parameters and of standardizing the experiments, the

96

suppression of the water signal was skipped at first. Validation results proved that this approach was correct

97

since the high amount of water in the formulation (about 40:1 molar ratio in respect to active substance) did

98

not actually impair the correct evaluation of the content of iobitridol.

99

3.2.

us

Iobitridol FP assay

cr

ip t

90

The assay value of iobitridol FP was reported in the manufacturer’s certificate of analysis and it was

101

confirmed in our laboratory by repeating the analyses with the same manufacturer’s method. The method and

102

the relevant validation cannot be disclosed being confidential information reported in the Manufacturer’s

103

dossier for Marketing Authorization. Briefly, three different samples were assayed and found to have a

104

concentration of 34.3% (CV% = 0.31%; n=3). This value was in good agreement with the assay reported in

105

the manufacturer’s certificate of analysis (34.2%).

106

3.3.

107

The validation study was based on the ICH Q2 guidelines. The results obtained in the validation study were

108

considered satisfactory and in line with the expected performance already reported in literature. [20, 21].

109

3.3.1. Selectivity

110

Selectivity was demonstrated by showing that in the spectral zones where signals integrations were carried

111

out there was no interference of overlapping signals.

112

In general NMR 2D experiments can support selectivity by smoothly resolving in two dimensions signals

113

which are not separated in monodimensional spectra [20]. 2D H, H TOCSY and H, C HSQC were acquired

114

on iobitridol FP samples, the outcomes confirmed that no interfering signals affected quantification.

115

Furthermore, selectivity can be demonstrated by assessing the capability of the analytical method to provide

116

an exact result for the content of the analyte in a sample. This was confirmed by the results here obtained for

117

accuracy.

118

3.3.2 Accuracy

ed

M

an

100

Ac

ce pt

Validation

1

1

1

13

4 Page 6 of 15

Accuracy was carried out by analyzing three samples of iobitridol FP at about 80%, 100% and 120% by

120

weighing adequate amount of the drug product solution (between about 200 mg and 320 mg). Three

121

independent replicates for each level were prepared and each of these was analyzed in duplicate. The results

122

are reported in Table 1. Note that one of the samples (45%) referring to the 120% level is actually 131%. The

123

difference of +11% was not considered critical and it was included in the calculations.

124

The recoveries (ranging between 99.6% and 100.7%) were considered satisfactory also considering that the

125

analyzed sample is not a pure substance.

126

3.3.3 Precision

127

Repeatability was assessed by performing seven analyses of the same sample carried out by one analyst in

128

the same day. The CV% for the repeatability was 0.25%.

129

Intermediate precision was assessed by analyzing six independently prepared samples. The analyses and

130

sample preparations were carried out by two different analysts in two different days. The total CV% for the

131

intermediate precision was 0.38% (n=12).

132

Averages (and variances) obtained by two analysts on six independent samples were: 34.4% (0.0184) and

133

34.4% (0.0167). ANOVA analysis did not show any statistical difference: F=0.4308011 (Fcrit= 4,964603 -

134

p=005).

135

3.3.4 Linearity

136

Linearity was assessed by varying the amount of the tested samples in the range from 70% to 120% of the

137

target weight (260 mg) of the analytical procedure.

138

The relevant equation was y=0.1346x-0.763 (R =0.9985).

139

3.3.5 Robustness

140

The considered parameters and their variations were reported in Table 2.

141

The experiments were aimed to evaluate the recovery by changing one parameter in each experiment.

142

Robustness of the method was also evaluated on test solutions containing different sample/RS ratios (w/w).

143

In this case the robustness was checked by assessing the linearity of the integral of the iobitridol proton vs

144

the sample/RS ratios in the range +/-50% of the target ratio (Table 2).

145

The relevant equation was y=0.1391x-0.05321 (R =0.9994).

146

Data showed that the method is robust respect to sample/RS ratio variations.

147

3.3.6 Stability of the solution

ce pt

ed

M

an

us

cr

ip t

119

Ac

2

2

5 Page 7 of 15

148

Iobitridol is reported to be quite stable in alkaline solutions. In particular less than 2% degradation of iobitridol

149

in alkaline solution at pH 9 after three months at 50°C is reported [18].

150

Our experiments showed that the assay value of iobitridol is not affected by a 24 hours storage at 25°C when

151

dissolved in 1.4% w/w NaOH/D2O.

152 4.

Conclusion

ip t

153 154

1

In this report a quantitative H-NMR method for quantification of iobitridol in an injectable preparation was

156

developed and successfully validated with good results of accuracy and precision. It is expected that the

157

method is adequate also to quantify iobitridol as drug substance. The method does not require NMR

158

instrumentation equipped with high magnetic fields as validation proved successful on a magnet operating at

159

400 MHz which is nowadays quite common in pharmaceutical laboratories.

160

Furthermore the NMR method is more rapid and simple in comparison to assay determination based on

161

titrimetric and HPLC methodologies; it requires no specific reference standard, there is no need for sample

162

pretreatment and, because of short analysis times, it can be recommended for routine controls especially

163

when high sample throughput is required.

ed

M

an

us

cr

155

164 Acknowledgments

166

The authors acknowledge Mr. Tonino Puccio for technical assistance.

167

169

References: [1]

170 171

I. McEwen, A. Amini, I.M. Olofsson, Identification and purity test of heparin by NMR - a summary of

Ac

168

ce pt

165

two years' experience at the Medical Products Agency, Pharmeur. Bio. Sci. Notes 1 (2010) 65-72. [2]

,

T. Beyer, B. Diehl, G. Randel, E. Humpfer, H. Schäfer, M. Spraul, C. Schollmayer, U. Holzgrabe, 1

172

Quality assessment of unfractionated heparin using H nuclear magnetic resonance spectroscopy, J.

173

Pharm. Biomed. Anal. 48 (2008) 13–19.

174 175

[3]

U. Holzgrabe, Quantitative NMR spectroscopy in pharmaceutical applications, Prog. Nucl. Magn. Reson. Spectrosc. 57 (2010) 229-240.

6 Page 8 of 15

176

[4]

177 178

M. Malet-Martino, U. Holzgrabe, NMR techniques in biomedical and pharmaceutical analysis, 55 (2011) J. Pharm. Biomed. Anal. 1-15.

[5]

1

G F. Pauli, T. Gödecke,. B.U. Jaki, D.C. Lankin, Quantitative H NMR: Development and Potential of an Analytical Method – an Update, J. Nat. Prod. 75 (2012) 834–851.

179 [6]

S.K. Bharti, R. Roy, Quantitative 1H NMR spectroscopy, Trends Anal. Chem. 35 (2012) 5-26.

181

[7]

U. Holzgrabe, R. Deubner, C. Schollmayer, B. Waibel, Quantitative NMR spectroscopy—Applications

182

in drug analysis, J. Pharm. Biomed. Anal. 38 (2005) 806–812. [8]

cr

183

ip t

180

T. Rundlöf, I. McEwen, M. Johansson, T. Arvidsson, Use and qualification of primary and secondary standards employed in quantitative 1H NMR spectroscopy of pharmaceuticals, J. Pharm. Biomed.

185

Anal. (2013) available on line at

186

http://www.sciencedirect.com/science/article/pii/S0731708513004354.

188

an

[9]

P.L. McCormack, Iobitridol: a review of its use as a contrast medium in diagnostic imaging, Clin. Drug. Investig. 33 (2013) 155-166.

M

187

us

184

[10]

Iodixanol European Pharmacopoeia 7.0 07/2010:2215.

190

[11]

Iohexol European Pharmacopoeia 7.0 01/2008:1114.

191

[12]

Iopamidol European Pharmacopoeia 7.0 01/2008:1115.

192

[13]

Iopanoic acid European Pharmacopoeia 7.0 01/2008:0700.

193

[14]

Iotalamic acid European Pharmacopoeia 7.0 01/2008:0751.

194

[15]

P. Bourrinet, H. Feldman, A. Dencausse, C. Chambon, B. Bonnemain, High-performance liquid

ce pt

ed

189

chromatographic determination of iobitridol in plasma, urine and bile, J. Chromatogr. B 670 (1995)

196

369–372.

197

[16]

198 199

M. F. Summers, L. G. Marzilli, A. Bax, Complete 1H and I3C Assignments of Coenzyme B12 through the Use of New Two-Dimensional NMR Experiments, J. Am. Chem. Soc. 108 (1986) 4285-4294.

[17]

200 201

Ac

195

N. E. Jacobsen, NMR Spectroscopy Explained: Simplified Theory, Applications and Examples for Organic Chemistry and Structural Biology, John Wiley & Sons, West Sussex, 2007, pp. 489-550.

[18]

D. Meyer , M. Petta, M.H. Fouchet, M. Vadel, M. Schaefer, M. Dugast-Zrihen, M. Guillemot,

202

Stabilization of the hydrophilic sphere of iobitridol, a new nonionic iodinated contrast agent, Acta

203

Radiol. 37 (1996) 8-16.

7 Page 9 of 15

204

[19]

205

E. Gaidamauskas, E. Norkus, E. Butkus, D.C. Crans, G.˙Grinciené,˙ Deprotonation of β-cyclodextrin in alkaline solutions, Carbohydr. Res. 344 (2009) 250–254.

206

[20]

F. Malz, H. Jancke, Validation of quantitative NMR, J. Pharm. Biomed. Anal. 38 (2005) 813–823.

207

[21]

G. Maniara, K. Rajamoorthi, S. Rajan, G.W. Stockton

Method performance and validation for

quantitative analysis by (1)H and (31)P NMR spectroscopy. Applications to analytical standards and

209

agricultural chemicals, Anal. Chem. 70 (1998) 4921-4928.

Ac

ce pt

ed

M

an

us

cr

ip t

208

8 Page 10 of 15

Table 1

Table 1

26.3%

26.2%

99.6%

80%

28.2%

28.4%

100.7%

80%

26.7%

26.6%

99.8%

100%

35.3%

35.2%

99.7%

100%

34.3%

34.4%

100.5%

100%

33.4%

33.5%

100.6%

120%

39.8%

39.9%

100.3%

120%

39.7%

39.9%

100.3%

131% a

45.0%

44.9%

99.9%

a

The difference of +11% between 120% and 131% was not considered critical and it was included in the calculations.

Mean = 100.1%

0.41%

Ac

ce pt

ed

M

CV% =

ip t

80%

a

Recovery (%)

cr

Found (n=2)

us

Theoretical

an

Level

Page 11 of 15

Table 2

Table 2 Parameter target valuea

Modified parameters

Recovery

P1 =4 0°

100.3%

P1 = 50°

100.3%

Number of scans = 12

99.7%

Number of scans = 20

99.8%

D1 = 25 sec

100.0%

D1 = 35 sec

100.2%

O1p = 4.2

100.9%

O1p = 5.2

100.4%

Receiver gain = 3

99.5%

Receiver gain = 6

100.6%

Temperature = 296 K

99.8%

Temperature = 300 K

100.6%

P1= 45°

ip t

Number of scans = 16

cr

D1 = 30 s

an

Receiver gain = 5

M

Temperature = 298 K

NaOD = 1.2%

100.9%

NaOD 1.4% NaOD % = 1.6%

100.6 %

ce pt

ed

P1 = applied pulse; D1 = delay time, O1p = center of the spectral window.

Ac

a

us

O1p = 4.7 ppm

Page 12 of 15

h

us

g

cr

ip t

Figure 2

f

an

e d

M

c

b

Ac c

ep te

d

a

Page 13 of 15

Figure 1

HO

1

O O

I HN

OH

N OH I

I N

ip t

O

OH

2

ce pt

ed

M

an

us

cr

OH

Ac

HO

Page 14 of 15

Captions to figures

ip t

Figure 1 Chemical structure and IUPAC name of Iobitridol: 1-N,3-N-bis(2,3-dihydroxypropyl)-5-[3-hydroxy-2(hydroxymethyl)-1-oxopropylamino)]-2,4,6-triiodo-1-N,3-N-dimethylbenzene-1,3-dicarboxamide. Proton 1 was integrated for quantification.

Ac ce p

te

d

M

an

us

cr

Figure 2 Preliminary studies on the solvent/ reference standard system: Effect of NaOH concentration on the proton spectra Iobitridol and maleic acid in D2O. a: NaOH 0.1%; b: NaOH 0.3%; c: NaOH 0.7%; d: NaOH 1.5%; e: NaOH 2.0%; f: NaOH 2.5%; g: NaOH 5.0 %; h: From bottom to top NaOH 1.2%, 1.3% and 1.4%. NMR were acquired on a Bruker AV 700 MHz The integral of the multiplet under the arrow was selected for quantification.

Page 15 of 15